Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

MammoSite therapy delivers targeted radiation directly to the area where breast cancer is most likely to recur, allowing a full course of radiation to be delivered in just five days, limiting radiation exposure to normal, healthy tissue.

Hologic, Inc.(Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced that the six-year follow-up results from the MammoSite Registry Study continue to show promising results for breast cancer patients. The results were presented at the American Society of Radiation Oncology (ASTRO 2011) meeting in Miami, Florida, October 3. Hologic featured its next-generation MammoSite ML (multi-lumen) radiation therapy system at ASTRO, the largest radiation oncology medical show in the world.

The American Society of Breast Surgeons (ASBS) MammoSite Registry of more than 1,400 patients shows "excellent/good" cosmetic results in 90.4 percent of the cases. Hologic's MammoSite system is the only breast brachytherapy balloon system with six years of follow-up registry data.

According to Peter Beitsch, M.D., FACS, a surgeon at the Dallas Breast Center in Texas and lead author of the study, "The ASBS MammoSite Registry has contributed to the acceptance of Accelerated Partial Breast Irradiation (APBI) across this country and the world by the reassuring long-term data on local control, lack of risk of regional recurrence in the era of the sentinel node biopsy, and the comparable long-term survival after whole breast irradiation."

Carter Houghton, Vice President and General Manager of Hologic's Interventional Breast Solutions business, added, "The MammoSite Registry data provides further evidence supporting the use of MammoSite in early stage breast cancer patients. We are very pleased that the positive patient outcomes have remained strong over the course of six years with no statistically significant deterioration in the rate of excellent to good cosmetic results with time."

Source: Hologic, Inc.